Fluoroquinolones in the treatment of severe community-acquired pneumonia

被引：0

作者：

Wilcox, Mark H. ^{[1
]}

Finch, Roger ^{[2
]}

Wyncoll, Duncan ^{[3
]}

Gould, Kate ^{[4
]}

Howard, Philip ^{[5
]}

机构：

[1] Leeds Teaching Hosp NHS Trust, Leeds Gen Infirm, Old Med Sch, Dept Microbiol, Leeds LS1 3EX, W Yorkshire, England

[2] Univ Nottingham, Sch Mol Med Sci, Nottingham NG7 2RD, England

[3] Guys & St Thomas NHS Fdn Trust, Dept Anaesthet, London, England

[4] Newcastle Tyne Hosp Fdn Trust, Dept Microbiol, Newcastle, NSW, Australia

[5] Leeds Teaching Hosp NHS Trust, Dept Pharm, Leeds, W Yorkshire, England

来源：

BRITISH JOURNAL OF HOSPITAL MEDICINE | 2011年

关键词：

RESISTANT STAPHYLOCOCCUS-AUREUS; CLOSTRIDIUM-DIFFICILE; ANTIBIOTICS; TRIAL; CARE; LEVOFLOXACIN; GUIDELINES; MANAGEMENT; IMPACT; RATES;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Severe community-acquired pneumonia remains a leading cause of death in the UK despite the widespred use of recommended antibiotics. This article reviews the evidence for the use of fluoroquinolones in the treatment of severe community-acquired peumonia and argues for the inclusion of these agents in future guidelines.

引用

页码：S2 / S7

页数：6

共 28 条

[1]

ANDREWS BE, 1987, Q J MED, V62, P195

[2] Community-acquired pneumonia recovery in the elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy [J].

Anzueto, A ;

Niederman, MS ;

Pearle, J ;

Restrepo, MI ;

Heyder, A ;

Choudhri, SH .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (01) :73-81

[3]

Bayer Plc, 2011, SUMM PROD CHAR AV 40

[4] What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? [J].

Blondeau, J. M. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (02) :238-242

[5] Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus [J].

Bosso, John A. ;

Mauldin, Patrick D. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2106-2112

[6] Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial [J].

Bouadma, Lila ;

Luyt, Charles-Edouard ;

Tubach, Florence ;

Cracco, Christophe ;

Alvarez, Antonio ;

Schwebel, Carole ;

Schortgen, Frederique ;

Lasocki, Sigismond ;

Veber, Benoit ;

Dehoux, Monique ;

Bernard, Maguy ;

Pasquet, Blandine ;

Regnier, Bernard ;

Brun-Buisson, Christian ;

Chastre, Jean ;

Wolff, Michel .

LANCET, 2010, 375 (9713) :463-474

[7] Impact of different empirical antibiotic treatment regimens for community-acquired pneumonia on the emergence of Clostridium difficile [J].

Bruns, Anke H. W. ;

Oosterheert, Jan Jelrik ;

Kuijper, Ed J. ;

Lammers, Jan Willem J. ;

Thijsen, Steven ;

Troelstra, Annet ;

Hoepelman, Andy I. M. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (11) :2464-2471

[8] C-reactive protein is an independent predictor of severity in community-acquired pneumonia [J].

Chalmers, James D. ;

Singanayagam, Aran ;

Hill, Adam T. .

AMERICAN JOURNAL OF MEDICINE, 2008, 121 (03) :219-225

[9] Antibiotics for community-acquired pneumonia [J].

Dryden, Matthew ;

Hand, Kieran ;

Davey, Peter .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (06) :1123-1125

[10] Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment [J].

Finch, R ;

Schürmann, D ;

Collins, O ;

Kubin, R ;

McGivern, J ;

Bobbaers, H ;

Izquierdo, JL ;

Nikolaides, P ;

Ogundare, F ;

Raz, R ;

Zuck, P ;

Hoeffken, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1746-1754

← 1 2 3 →